India · Delayed Price · Currency is INR Beta Drugs Statistics
Total Valuation
Beta Drugs has a market cap or net worth of INR 15.17 billion. The enterprise value is 15.40 billion.
| Market Cap | 15.17B |
| Enterprise Value | 15.40B |
Important Dates
The last earnings date was Tuesday, November 4, 2025.
| Earnings Date | Nov 4, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Beta Drugs has 10.09 million shares outstanding. The number of shares has decreased by -22.61% in one year.
| Current Share Class | 10.09M |
| Shares Outstanding | 10.09M |
| Shares Change (YoY) | -22.61% |
| Shares Change (QoQ) | -50.00% |
| Owned by Insiders (%) | 1.05% |
| Owned by Institutions (%) | n/a |
| Float | 3.36M |
Valuation Ratios
The trailing PE ratio is 28.02.
| PE Ratio | 28.02 |
| Forward PE | n/a |
| PS Ratio | 3.93 |
| PB Ratio | 6.86 |
| P/TBV Ratio | 7.16 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 60.22 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 20.35, with an EV/FCF ratio of -43.84.
| EV / Earnings | 36.76 |
| EV / Sales | 3.99 |
| EV / EBITDA | 20.35 |
| EV / EBIT | 24.83 |
| EV / FCF | -43.84 |
Financial Position
The company has a current ratio of 3.09, with a Debt / Equity ratio of 0.66.
| Current Ratio | 3.09 |
| Quick Ratio | 2.12 |
| Debt / Equity | 0.66 |
| Debt / EBITDA | 1.93 |
| Debt / FCF | -4.15 |
| Interest Coverage | 5.24 |
Financial Efficiency
Return on equity (ROE) is 20.85% and return on invested capital (ROIC) is 18.91%.
| Return on Equity (ROE) | 20.85% |
| Return on Assets (ROA) | 9.91% |
| Return on Invested Capital (ROIC) | 18.91% |
| Return on Capital Employed (ROCE) | 16.61% |
| Weighted Average Cost of Capital (WACC) | 2.81% |
| Revenue Per Employee | 9.67M |
| Profits Per Employee | 1.05M |
| Employee Count | 399 |
| Asset Turnover | 0.99 |
| Inventory Turnover | 3.65 |
Taxes
In the past 12 months, Beta Drugs has paid 143.84 million in taxes.
| Income Tax | 143.84M |
| Effective Tax Rate | 25.56% |
Stock Price Statistics
The stock price has decreased by -15.84% in the last 52 weeks. The beta is -0.32, so Beta Drugs's price volatility has been lower than the market average.
| Beta (5Y) | -0.32 |
| 52-Week Price Change | -15.84% |
| 50-Day Moving Average | 1,612.89 |
| 200-Day Moving Average | 1,754.80 |
| Relative Strength Index (RSI) | 39.63 |
| Average Volume (20 Days) | 4,605 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Beta Drugs had revenue of INR 3.86 billion and earned 418.99 million in profits. Earnings per share was 53.63.
| Revenue | 3.86B |
| Gross Profit | 1.53B |
| Operating Income | 620.41M |
| Pretax Income | 562.83M |
| Net Income | 418.99M |
| EBITDA | 756.73M |
| EBIT | 620.41M |
| Earnings Per Share (EPS) | 53.63 |
Balance Sheet
The company has 1.23 billion in cash and 1.46 billion in debt, with a net cash position of -231.88 million or -22.97 per share.
| Cash & Cash Equivalents | 1.23B |
| Total Debt | 1.46B |
| Net Cash | -231.88M |
| Net Cash Per Share | -22.97 |
| Equity (Book Value) | 2.21B |
| Book Value Per Share | 437.84 |
| Working Capital | 2.39B |
Cash Flow
In the last 12 months, operating cash flow was 251.92 million and capital expenditures -603.27 million, giving a free cash flow of -351.35 million.
| Operating Cash Flow | 251.92M |
| Capital Expenditures | -603.27M |
| Free Cash Flow | -351.35M |
| FCF Per Share | -34.81 |
Margins
Gross margin is 39.68%, with operating and profit margins of 16.09% and 10.86%.
| Gross Margin | 39.68% |
| Operating Margin | 16.09% |
| Pretax Margin | 14.59% |
| Profit Margin | 10.86% |
| EBITDA Margin | 19.62% |
| EBIT Margin | 16.09% |
| FCF Margin | n/a |
Dividends & Yields
Beta Drugs does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 22.61% |
| Shareholder Yield | 22.61% |
| Earnings Yield | 2.76% |
| FCF Yield | -2.32% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on March 26, 2025. It was a forward split with a ratio of 1.05.
| Last Split Date | Mar 26, 2025 |
| Split Type | Forward |
| Split Ratio | 1.05 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |